Auxogyn acquired exclusive license to develop noninvasive embryo assessment technology that can predict human embryo fate at the four-cell stage, allowing for improved IVF procedures and higher live birth rates. The licensed technology demonstrates a high degree of accuracy in predicting blastocyst formation.
Plexxikon's V600E B-Raf inhibitor demonstrated robust efficacy in xenograft models using a once-daily low oral dose, showing tumor shrinkage and prolonged delay of tumor growth. The company intends to file an IND application and initiate Phase 1 clinical trials for the oncogenic B-Raf inhibitor.
Scientists at Galileo Pharmaceuticals confirm a significant link between inflammation and glucose regulation in metabolic disease. The study demonstrates that administration of a proprietary dual 5- and 15-lipoxygenase inhibitor reduces resting glucose levels by approximately 20% without affecting insulin levels.
A triple therapy study using ZADAXIN in combination with pegylated interferon alpha and ribavirin showed a 61% response rate for patients with hepatitis C who were non-responders to previous treatment. The study found that ZADAXIN improved response rates for these patients.